A recent international study has found that the effectiveness of beta blocker drugs after a heart attack may depend on individual patient characteristics, including gender and specific heart conditions. The findings could lead to changes in clinical guidelines for treating cardiovascular disease.
Beta blockers have long been used as a standard treatment following heart attacks and are also prescribed for high blood pressure, arrhythmias, and congestive heart failure. However, new research suggests their benefits may not be universal.
The REBOOT trial (Treatment with Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction) followed 8,505 patients across 109 hospitals in Spain and Italy. Participants were randomly assigned either to receive beta blockers after hospital discharge or not, while all received standard follow-up care. The study found no significant difference between the two groups regarding recurrent heart attacks, hospitalization for heart failure, or death rates.
Notably, women with normal cardiac function—defined as a left ventricular ejection fraction of 50% or higher—who took beta blockers had a 2.7% higher risk of mortality over nearly four years compared to those who did not take the medication. This increased risk was not observed in men.
“It will make every cardiologist rethink treatment,” said Claudia Martinez, M.D., an interventional cardiologist with the University of Miami Health System. “And it will lead to more precision medicine, treatment tailored to the patient.”
Dr. Martinez emphasized that patients should consult their doctors before making any changes to their medication regimen: “Speak to your cardiologist about any change in medication or treatment.”
She added that understanding how beta blockers affect women is beneficial because some recovering patients might avoid unnecessary side effects if they can safely skip these medications.
Patients with reduced ejection fraction (less than 40%) or those with arrhythmias continue to benefit from beta blockers. These drugs remain important for managing abnormal heart rhythms and preventing further cardiac events in these populations.
“We have been using them for years and years. They will continue to be standard treatment for the population that needs them,” Dr. Martinez said.
Since their introduction in the 1960s, treatments for heart attacks have advanced significantly; immediate interventions now include blood thinners and stents along with improved preventive therapies such as better imaging techniques.
A statement from the American College of Cardiology supported the findings: “For patients with no signs of heart failure and a normal ejection fraction, this trial establishes that there’s no indication that routine use of beta blockers is beneficial.”
The REBOOT study highlights the importance of gender-specific approaches in medical care. Historically, most cardiovascular research focused on men; results were often generalized across genders despite physiological differences such as smaller hearts and different responses to blood pressure medications among women.
“We are moving toward treatment that is more specific both in gender and ethnicity,” Dr. Martinez explained. One-size-fits-all medicine misses key differences: “By directing research and treatment it has been shown that we can improve outcomes.”
About 10% of people in the United States take beta blockers according to data from the National Center for Health Statistics.
Beta blockers work by blocking adrenaline’s effects on the body—slowing down heart rate, reducing stress on the heart muscle, and relaxing blood vessels—and are also used for other conditions like glaucoma, overactive thyroid disease, essential tremor, and portal hypertension.
